Innovative Diagnostic Technology Blinktbi's FDA-cleared EyeStat™ leverages advanced light and videography to deliver rapid, objective assessments of blink reflexes, positioning the company as a leader in neurological diagnostic tools with strong growth potential in medical device markets.

Strong Funding Momentum The recent Series C funding of $6.23 million enhances Blinktbi's financial stability and capacity for product development and market expansion, indicating investor confidence and a significant opportunity for partners to collaborate on scaling efforts.

Expanding Application Scope While initial focus is on traumatic brain injury detection, Blinktbi’s exploration into neurological diseases such as Parkinson’s, Alzheimer’s, and migraines broadens potential customer bases, including hospitals, clinics, and research institutions seeking innovative diagnostic solutions.

Market Competitiveness Operating in the competitive CNS diagnostics space with similar firms, Blinktbi's unique FDA clearance and focus on rapid, non-invasive assessments can provide a competitive advantage and appeal to healthcare providers looking for efficient diagnostic tools.

Growth Opportunity in CNS Sector With a revenue range of 1 to 10 million and engagements in neurological health, there is a substantial opportunity to partner with healthcare facilities, research centers, and neurological clinics investing in cutting-edge diagnostic technologies for early detection and management of neurological conditions.